20 results
8-K
EX-99.1
GLYC
GlycoMimetics Inc
5 Mar 19
Glycomimetics Announces Transition Plan for Board of Directors
5:24pm
. Over the years, he has helped GlycoMimetics in innumerable ways through his strong leadership and unwavering dedication to the company. I also extend … leadership of GlycoMimetics’ research efforts in his role as Senior Vice President, Research and CSO,” said Chief Executive Officer, Rachel King. “I’m also
8-K
EX-99.2
GLYC
GlycoMimetics Inc
5 Aug 21
Glycomimetics Reports Highlights and Financial Results
8:01am
Board, I offer sincere thanks to Rachel for her leadership of GlycoMimetics and for her commitment to the company’s employees and to patients who … commercialization of uproleselan. He possesses the right leadership and operational skills as well as tremendous know-how from his many years at Novartis
8-K
EX-99.1
GLYC
GlycoMimetics Inc
4 Oct 22
Regulation FD Disclosure
5:03pm
Key Leadership Hires in Last Year purpose-driven biotechnology team Deep expertise in regulatory, medical and commercialization across hem … transfer and process validation.October202244 leadership hires in last 12 months to build team with commercialization expertise
Unmet need continues
PRE 14A
GLYC
GlycoMimetics Inc
22 Mar 24
Preliminary proxy
5:00pm
and characteristics, leadership traits, work ethic, and independence to provide effective oversight. No director or executive officer is related by blood, marriage … as one of our co-founders and her experience with biotechnology companies prior to founding our company, in addition to her leadership skills, allow
8-K
EX-99.1
htiprvgfevpa457i4
28 Nov 18
Scott Jackson, Veteran Biopharmaceutical Executive, Joins Glycomimetics Board of Directors
4:00pm
8-K
EX-99.1
vtrzn17r2f
7 Jan 20
GLYCOMIMETICS AND APOLLOMICS Announce Exclusive Collaboration and License Agreement to Develop and Commercialize UPROLESELAN and GMI-1687
4:00pm
8-K
EX-99.1
642xdlorlixukh0753hv
1 Mar 24
Regulation FD Disclosure
9:16am
8-K
EX-99.1
z3bxwyt6o jwwo
27 Mar 24
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023
9:00am
10-K
5h33kxlys2h2m0k
31 Mar 14
Annual report
12:00am
S-1
ro9dd3a
4 Oct 13
IPO registration
12:00am
424B4
rd5vhp0aa13gu81
10 Jan 14
Prospectus supplement with pricing info
12:00am
- Prev
- 1
- Next